The problem with neoantigen prediction

Personalized immunotherapy is all the rage, but neoantigen discovery and validation remains a daunting problem.

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 35; no. 2; p. 97
Main Author Anon
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.02.2017
Nature Publishing Group
Subjects
631/154
631/61/212/2166
692/699/67/1059/2325
Agriculture
Algorithms
Antigens
Antigens, Neoplasm
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedical Research
Biomedicine
Biotechnology
Cancer Vaccines
Computational Biology
editorial
Exome sequencing
Humans
Identification and classification
Immune system
Life Sciences
Methods
Models, Statistical
Neoplasms - immunology
Neoplasms - prevention & control
Peptides
Physiological aspects
Proteins
Software
Tumor antigens
Tumors
Online AccessGet full text

Cover

More Information
Summary:Personalized immunotherapy is all the rage, but neoantigen discovery and validation remains a daunting problem.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt.3800